Group 1 - The market perceives that companies listed on the Hong Kong stock market benefit from being included in the Hong Kong Stock Connect, as it attracts southbound capital and enhances company visibility [1] - Brain动极光-B (06681.HK) experienced a significant price increase, rising by 32% last Friday and peaking at over 80% before a notable pullback, ultimately trading at HKD 10.4, reflecting a nearly 40% increase [1] - Since entering the Hong Kong Stock Connect, Brain动极光-B has seen its stock price nearly double, with a peak increase exceeding 100% within a week [1] Group 2 - Brain动极光 is the first Chinese company to combine brain science with advanced artificial intelligence to develop medical-grade digital therapy products for cognitive impairments [3] - The company's product pipeline addresses a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children [3] - In the first half of this year, Brain动极光 reported revenue of RMB 100 million, marking a year-on-year growth of 92.82% [3] Group 3 - Other stocks that entered the Hong Kong Stock Connect on September 8 also experienced significant price increases, such as药捷安康-B (02617.HK) with a cumulative rise of over 220% and映恩生物-B (09606.HK) with a cumulative rise of over 30% [3]

格隆汇9月15日｜港股市场脑机接口概念股脑动极光-B(6681.HK)拉升大涨超80%，报13.78港元，为连续 第三日上涨，股价创上市新高，截至目前成交额放大至7亿港元。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

格隆汇9月15日｜港股市场脑机接口概念股脑动极光-B(6681.HK)拉升大涨超80%，报13.78港元，为连续 第三日上涨，股价创上市新高，截至目前成交额放大至7亿港元。 ...

Core Viewpoint - Brainstorming Aurora-B (06681) experienced a significant stock price increase, reaching a new high since its listing, following its inclusion in the Hong Kong Stock Connect program [1] Group 1: Stock Performance - The stock surged over 83% in early trading, peaking at 13.78 HKD, marking a cumulative increase of 1.3 times since its market entry [1] - As of the report, the stock was up 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] Group 2: Company Developments - Starting from September 8, Brainstorming Aurora was officially included in the Hong Kong Stock Connect list [1] - The company is recognized as the first in China to develop medical-grade digital therapy products targeting cognitive disorders, with its core product being the first to receive regulatory approval in this category (registered in September 2018) [1] - On September 12, the company announced via its official WeChat account that its series of products received the Beijing New Technology, New Product, and New Service Certificate [1] Group 3: Product Features - The products focus on intelligent assessment and precise intervention, boasting several advantages: reliance on large sample norms for accurate evaluation, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

Core Viewpoint - Brain动极光-B (06681) has seen a significant stock price increase, rising over 83% to a new high of 13.78 HKD since its listing, with a cumulative increase of 1.3 times since its debut [1] Group 1: Stock Performance - As of the latest update, the stock price has increased by 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] - The stock was officially included in the Hong Kong Stock Connect list starting September 8 [1] Group 2: Company Overview - Brain动极光 is the first domestic company to develop medical-grade digital therapy products targeting cognitive disorders [1] - Its core product is the first cognitive disorder digital therapy product in China to receive regulatory approval, obtaining its first registration certificate in September 2018 [1] Group 3: Product Features - The company's products have recently received the Beijing New Technology, New Product, and New Service Certificate [1] - The products focus on intelligent assessment and precise intervention, featuring advantages such as precise evaluation based on large sample norms, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

9月12日，脑动极光(06681.HK)涨超50%，高见9.47港元创上市新高。截至发稿，涨50.44%，报8.52港 元，成交额5.79亿港元。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Brainstorm Aurora (06681), which rose over 50% to reach a new high of 9.47 HKD following its inclusion in the Hong Kong Stock Connect program effective September 8, 2025 [1] - As of the report, the stock was trading at 8.52 HKD with a trading volume of 579 million HKD, reflecting strong market interest [1] - The company reported a revenue of 100 million HKD for the first half of 2025, representing a year-on-year increase of 92.82% [1] Group 2 - The company has made significant advancements in its core pipeline in research and clinical trials, achieving commercialization for eight indications across four major types of cognitive disorders [1] - Additionally, the company is actively developing treatments for other cognitive disorder indications [1] - The company is pushing for innovation and application of AI in the medical field, having developed a proprietary medical large model, BrainAuGPT, which received a national invention patent for its novel training task combination method based on GBR second-order knowledge representation [1]

Core Viewpoint - Brain动极光 (06681) has seen a significant stock price increase of over 50%, reaching a new high of 9.47 HKD following its inclusion in the Hong Kong Stock Connect program, effective September 8, 2025 [1] Financial Performance - For the first half of 2025, the company reported revenue of 100 million HKD, representing a year-on-year increase of 92.82% [1] Product Development and Innovation - The company has made substantial progress in research and clinical trials for its core pipeline, achieving commercialization for eight indications across four major types of cognitive disorders [1] - The company is also advancing AI innovations in the medical field, with its self-developed medical large model, BrainAuGPT, receiving a national invention patent for a novel training task combination method based on GBR second-order knowledge expression [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 更改於開曼群島的註冊辦事處地址 腦動極光醫療科技有限公司（「本公司」）董事會（「董事會」）宣佈，本公司於開 曼群島的註冊辦事處的地址已更改，自2025年6月1日起，至#4-210, Governors Sq., 23 Lime Tree Bay Avenue, PO Box 32311, Grand Cayman KY1-1209, Cayman Islands。 承董事會命 腦動極光醫療科技有限公司 譚錚先生 主席兼執行董事 香港，2025年9月11日 截至本公告日期，董事會包括：(i)執行董事譚錚先生；(ii)非執行董事李思睿先 生、李明秋女士及Deng Feng先生；及(iii)獨立非執行董事林曉波先生、段濤博士 及李月中先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | 0 | | | USD | | 0 | | 本月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD ...